neratinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms, Neoplasms
Trial Timeline
Aug 4, 2006 → Jan 30, 2018
NCT ID
NCT00300781About neratinib
neratinib is a phase 2 stage product being developed by Puma Biotechnology for Breast Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00300781. Target conditions include Breast Neoplasms, Neoplasms.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasms were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05919108 | Phase 2 | Recruiting |
| NCT04781374 | Phase 2 | Withdrawn |
| NCT03812393 | Phase 2 | UNKNOWN |
| NCT00878709 | Phase 3 | Completed |
| NCT00864487 | Phase 1 | Completed |
| NCT00814060 | Phase 1 | Completed |
| NCT00757809 | Phase 1 | Completed |
| NCT00550212 | Phase 1 | Completed |
| NCT00498745 | Phase 1 | Completed |
| NCT00397046 | Phase 1 | Completed |
| NCT00380328 | Phase 1 | Completed |
| NCT00300781 | Phase 2 | Completed |
| NCT00366600 | Phase 1 | Completed |
| NCT00146172 | Phase 1 | Completed |
Competing Products
20 competing products in Breast Neoplasms